<SEC-DOCUMENT>0000000000-18-037813.txt : 20190129
<SEC-HEADER>0000000000-18-037813.hdr.sgml : 20190129
<ACCEPTANCE-DATETIME>20181212081928
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-18-037813
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20181212

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aptorum Group Ltd
		CENTRAL INDEX KEY:			0001734005
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		UPLOAD

	BUSINESS ADDRESS:	
		STREET 1:		17/F, GUANGDONG INVESTMENT TOWER
		STREET 2:		148 CONNAUGHT ROAD CENTRAL
		CITY:			HONG KONG
		STATE:			F4
		ZIP:			999077
		BUSINESS PHONE:		852 2117 6611

	MAIL ADDRESS:	
		STREET 1:		17/F, GUANGDONG INVESTMENT TOWER
		STREET 2:		148 CONNAUGHT ROAD CENTRAL
		CITY:			HONG KONG
		STATE:			F4
		ZIP:			999077
PUBLIC REFERENCE ACCESSION NUMBER:		0001213900-18-012108
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
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MA8'C ,/Q,I8 '@Y^!T4',8>V!H;_]2!Y-$$DP K%# P[@*8(,# HSQ"-L5L
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M<F5A;0T*>)SMP8$     PR!_ZMW@!%4!
M
M
M
M
M
M
M
M      #/ %&5NID-"F5N9'-T<F5A;0UE;F1O8FH-,C<@,"!O8FH-/#PO0FET
M<U!E<D-O;7!O;F5N=" X+T-O;&]R4W!A8V5;+T-A;%)'0CP\+T=A;6UA6S(N
M,B R+C(@,BXR72]-871R:7A;,"XT,3(S.2 P+C(Q,C8T(# N,#$Y,S,@,"XS
M-3<U." P+C<Q-3$W(# N,3$Y,3D@,"XQ.# T-2 P+C W,C$X(# N.34P-%TO
M5VAI=&50;VEN=%LP+CDU,#0S(#$@,2XP.5T^/ETO1FEL=&5R+T9L871E1&5C
M;V1E+TAE:6=H=" R-#<O26YT96YT+U!E<F-E<'1U86PO3&5N9W1H(#(T.30Q
M+U--87-K(#(V(# @4B]3=6)T>7!E+TEM86=E+U1Y<&4O6$]B:F5C="]7:61T
M:" Q-#(X/CYS=')E86T-"GB<[9WK5>,Z%$;3 BU,"VEA6J %6J %6J %6J %
M6J %6O ]*WOEK(,D*\X#9H:[]P]6<&19EAU+^GP>RR(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B+_-A\?'^_O[V]O;Z^OKR\'GI^?GP[$AY="
M%(AB43AV^=.M%A$1$1$1$9$?2,H4S\_/CX^/]_?WOP[<'=E-R6+L]?OW[ZCA
MZ>GI]?5504-$1$1$1$1$+N;M[>WIZ>GAX6&_WS<"Q:]?O^[O[^.KQW.(\K]_
M_VZJBLJ1,EY>7M0Q1$1$1$1$1&3"Q\<'QA6_?__&K *98K_?QY;8?A/O#TPX
M@I>7%X21/%;\C7_3)..&IR8B(B(B(B(B_S1O;V^/CX_5*"(^QY;GY^?M2@6B
M1/]YSL>!EY<7O%&R ?O]_N'A(;9??E8B(B(B(B(B\H^#5P@N(=@\/#P\;+%Y
MB +89F1$B_P<-7Q\?-S?WZ=72)2,HZ2;2=4TL.*H-<>^T8#'Q\=T5&''V*A'
MB8B(B(B(B,C_A]?75T)NHCQ@X;#=3>/CXR-V2>&"9"+H%?%W.8@2J68\/S_'
MO_O]'AT#[2)VP<R#>!?#0T2=<91L)!J("H:(B(B(B(C(#^;]_?WY^3G5@/O[
M^SY")I$HTG B"@\=-V(OZOG]^_=R$$.B<N)74&%LH0:.$A^>GI[8]_'QD:](
MJ)HJ1]0PE% :$0/CD"_I(!$1$1$1$1'Y0WQ\?*1[R*]?O_#=2-6"H!-1($->
MD/LC_DW]H:^0;Z,\3B($QXB-B ^Q$5L+CI@UH&/4.MD2Q:))%(Y*>G4BJN44
M4GA1P1 1$1$1$1'Y ;#DQVB!+![5T +) N.*:@(1GY>B/P2]]47:9CP^/J8Z
M42N/FM-X(ZTILL(:^"+M-U(M09T@7FAC&8)9"#$Z5#!$1$1$1$1$_EUBR1\+
M_[2UZ(-%O+^_IQD#7T7Y3/-!F=0??O_^W>Q>_4K2CJ*6B?HSWB9*17R;TD3U
M#4%4P>XB;3 R: :6&+4\T3!2P6A"@(J(B(B(B(C(WP_!,%GX-ZI%>HN0G!0)
M@BWO[^\I%V29S%O:6#ADN,[8Z_[ <A TTD(CE1!L,ZA_J(20B37+IPR21AJQ
M9:A.9(S0:' <PDB>(B(B(B(B(G\_L<9_>'C UJ)9SL=*/\TP\BO,&] 6EN*U
MD1)$"@AKVD74$Y508?J;1&$L(M+08BG:11ZNDH8<'"C-,#+^YQIY7M'X8611
M$1$1$1$1$?D;P'0!PXFA&T6J$.D8PDJ_Y@?)6)HI+Z3^T&@7F2Z$2@B=P;_8
M;]S?WQ/&,XNESTC5+LAL$A_2P(-(H7E<Q) &?$R:<\>%)"K?GN]51$1$1$1$
M1+Z'6,B3)62_WZ\%?X@%?L:X2'#'J!)$1K% S4"C( 9%K2JUB_B0OAM((J@0
M#P\/1 K-[5$,NX[X*JN*';&7R.-FNI/:C'KHOA(@3RN=H &&B(B(B(B(R-\#
MYA:Q9J^A+0AG,2R,VTC*%YF%A +I-H)8@49!'I!:R:X#V>'^_C[EBTQQ4BT]
ML([(RFEV2A]86?110_.D4GN)O;;WAHB(B(B(B(C\$; T8(W?F%M@3='G!UD.
MZ@3I1QL;#+2.:BF!<-$;/\1Q7U]?/XY,6HBQ1Q0F#2N*2@H:Q,2((V:&$?9J
M'%+RC%(5V7WV86E"DJ:O2I.@1$1$1$1$1$2^$_Q$\)[H!02TB]THUB7J :I"
MJ@2[8X*/U"[2)>3D\O]CA4G+7P[$A]?7UVJYL7PVKLA*"/Y)0I-J%@((.$38
MR"9Q(OBJ;.U3$1$1$1$1$;D1Z7RQ%M@AM0LT@29:1<TM0I+3-&; ]:./]AE[
MQ;?/!Z)\=08Y":$[GYZ>8E^">3;G$H>CPL<#[)6.*FQ!A<BOJC:R%E"4TXE>
M&@;\%!$1$1$1$9$O(F-6K(7E7$I,RZ%\\?CX&%NJAD @S=@2Q:KU OE/XZOT
MUT S28GCY<AK@2VQ(RK'W9%L#/OB>,*Q<"WAU%*@B"UI4U%KJ($ZJTJ#=D'X
MT/R6X)_#Q*PB(B(B(B(B<ELRP<>62 Y(!^E_4<T/8E_R<9 -I-DQMD3)-&;@
M<%';T]/3-?X742V"!EE9:^5-SE.*I6D'2D63W"0[!%VET2YVG[U=.)?AR8J(
MB(B(B(C(K2 $)?$MMV30P%ZBFB7LCDE12>01554-A$":L05+B?B+YT@4N'G"
M#BPZ\G T9K_?/ST]97N04'X=0-G(9J>$0NR.S$O"=C*NDFHDCXA%1YR^\H6(
MB(B(B(C(5Y I1;;[/F1,C/U^GQ$MT@8CZDE3AUCRDZYT: 7Q#32&%M':V)*"
MR?/S<[0G3C^=5O@J^B1VP3^%'4EE0GB-/EZH\H6(B(B(B(C(%Q%K;8)7I"$!
M4L9\#1XK=S0*EO!('W7Q3OA-PD&09O0K3"RV4]M#6(SGY^?J]Y':!>V,$R%H
M9VH73P<(Y4$BE;<#60GY2LR=*B(B(B(B(G)#,@](6ES$ IPM^_U^;B 1JWC<
M*+!&J E#\=? T*(:.?P-Q$D]/3U5!8/FQ79./-K,!TX_M0OT#>PT\*^I=B94
MCCF*UA<B(B(B(B(B-R'3A:3%!;$=]OM]YOZ8Q,_,'!^Y_%^.*47^?O.#:' T
MFSB<C8+!QLR4FMH%\@7J1*H6L06/F.Q#K2]$1$1$1$1$;D(LS)L8%QG,(?^-
M=7HLR>/O<'>6\!D $T\3ENW79 SY3N(LT@8C[4;8V 3G1*D@>B?_IME)0+;6
MS+2"?$%8C#]U:B(B(B(B(B+_.GUP3E;<V _41?W0?R0*UY@81*JL;B/_%AE-
MM,;KX"NZA5B=&94TSK2:5="9L3&W8)ZQ,6F+B(B(B(B(B#2@2\3*NFY\>WO+
M[*7X353JPKQ"Q Q$CW]ZG1ZGCP<-Z47J]O0!R=YH)!J2L:;9!AO1<VHJ51$1
M$1$1$1'9 FOJC.<0?].F ON!1K*(C82PZ&TJ\*'X2;$=HG/P"DF3"4Q0R"V2
M"4=0;- E$#V0.Z*+JO')X^,C!AM_\(Q$1$1$1$1$_BUB6?WK0'I&8#5!ME."
M8!"!D\2FK-^C,/_6JD@8^J^;6_1DTMCX6SUET"YB(__B/T*0S\;!)'4>NK=&
MQA 1D>_AHW"R0%]F_NW)0PR_XF7!QP;>#ZPU9HT^.]BD\,9NG$"N\)<#,<RM
M94+G7#:VOZ_A9+//JG]CYTSVJKO'5W'B]$#-F2XB(B)7$J,JV4-R(,8P((-/
MYK#+$/Q1EN3Q;>Z%U4'=\O,@Y0KQ.=GR<0A/BKT*WZ891A9(7YOL9#;6OA41
MD:_FXR#%[P^LA1["4@X:A1D1.[\=FL_50S0%UHX>U1(;:@O9I%K;G"9&=',6
M?>&8 PS#<9^$F%<9%*O::E)G;09O.BYH?^Z>!8:MW5Y_6IPNQY<+6_9J'&S9
M-TYSWWG7$J8[;H8U&4=$1$0V@DM(3K&(Y!#C[]N!V)[6 CB#[ _S,=PHTMX
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M$1$1$1$1^:G@Q)$Q)6(5C.5#3<=)!A#L)?!H0'PXF3YC#0P,8@T>]6"T@#*
M6$&&UFK,D!^V+\_)5?I:N,PL(2TNB,9Y?W__< #A E>.C! 2_Y)"97N8BX8,
M";(<[2XPNN!<:K<TBE/L8K81$1$1$1$1^9&PYN4SK^]K# JVQXKXUX%81Z,
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M!%*>'X@G& XFB,9T13]=OTQZ6EM4;HFD-U3%UZPO;JA=5,'M7&?,DSXCP\"
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M!J\'B-N)J0#&$ND-414)U(/XZNE 7;^GJM!H%]46(DTUFA2HZ152W4/JW]J
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M$1$1$9%OYNWM#?VAL3%X?GY&><!P@L5^+.?S,XI'VF/4'7?'C!YI_) %4E+
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MT5$:[6*M)QO2**6>W= P1D1$1$1$1/X/L.*NRD/"V_9:;!CQ@!5K[S-"$(.
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MU5[(1NY..,9L]A2W0]2OX!YHU/,9;20,/BXFE%NQ&LFH9K"P[#!#= [% L&
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M37/;.!*]ZU>@?-ARJFPN/T2*VCEI\S792GD]$V_M)1>(A"3,D 0#@'*4>_[
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MABD)GH\&8"@71*W<0P\/I))YJ^W>;YSM@\MTR/[A,M___G)RW?=F,>!!ZF9
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MLK:3O!>L4$B?CSVK^9'="4:QE*4HOZ]@O06*9PG &<6<Y+%G.DJ64 ,:7PG
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MC9(LQ$G0TR^V>]26MD:=3WW7>GQ]? :A!C4/H]OS]>W%[7D4WEZ<?N-XBAE
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&)45/1@T*

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                             August 10, 2018

Ian Huen
Chief Executive Officer
Aptorum Group Ltd
17th Floor, Guangdong Investment Tower
148 Connaught Road Central
Hong Kong

       Re: Aptorum Group Ltd.
           Draft Registration Statement on Form F-1
           Submitted July 13, 2018
           CIK No. 0001734005

Dear Mr. Huen:

       We have reviewed your draft registration statement and have the
following comments. In
some of our comments, we may ask you to provide us with information so we may
better
understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Draft Registration Statement on Form F-1 Submitted July 13, 2018

Cover page

1.     Please amend your prospectus cover page to state the volume of
securities being offered
       on a minimum and maximum offering basis. Refer to Item 501(b)(2) of
Regulation S-K.
       Additionally, please expand your disclosure to include the date the
offering will end, any
       plans to place funds in escrow, or alternatively, that you have no such
plans. Refer to Item
       501(b)(8)(iii) of Regulation S-K.
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 2
Page 2
FirstName LastName
2.       We note your disclosure on page 6 and elsewhere that your Class B
ordinary shares are
         entitled to ten votes per share for any matter submitted for
shareholder approval. Please
         expand your cover page disclosure to briefly discuss your dual-class
structure and the
         relative voting rights of your Class A and Class B ordinary shares.
3.       We note that there is currently no public market for your Class A
ordinary shares, that you
         "plan to apply" to have this class listed on the Nasdaq Global Market,
and that the offering
         is conditioned on the "reasonable expectation" that the shares would
qualify for listing.
         We further note your disclosure that the selling shareholders may not
sell "on any trading
         market" until the shares are approved for listing, but that they may
sell in negotiated
         transactions. Please amend the cover page to indicate that the selling
stockholders will sell
         the shares at a fixed price until the shares are listed on the Nasdaq
and thereafter at
         prevailing market prices or privately negotiated prices.
Propsectus Summary
Overview, page 1

4.       We note from your disclosure that you have not yet conducted any
clinical trials. Terms
         such as "award-winning" and "first-in-class" suggest that the product
candidates are
         effective and likely to be approved. Please delete these references
throughout your
         registration statement. If your use of these terms was intended to
convey your belief that
         the products are based on a novel technology or approach and/or is
further along in the
         development process, you may discuss how your technology differs from
technology used
         by competitors and that you are not aware of competing products that
are further along in
         the development process. Statements such as these should be
accompanied by cautionary
         language that the statements are not intended to give any indication
that the product
         candidates have been proven effective or that they will receive
regulatory approval.
         Similarly, please remove the reference to
"First-in-Class/Best-in-Class innovations" on
         page 62 and the statements concerning the poster award and live
demonstration prize on
         page 73.
5.       We note your disclosure that you may develop formulations of your
therapeutic molecules
         which may qualify as nutraceuticals or some other product category
which may be subject
         to less regulation and provide a faster path to revenue generation.
Please expand your
         disclosure to identify the relevant product candidate(s) and the
contingencies to
         commercializing such product candidate(s) as nutraceuticals.
Alternatively, please delete
         this disclosure.
6.       We note your disclosure that you determined to pursue projects in your
non-therapeutics
         segment, such as the AML clinic, to provide some interim revenue.
Please balance your
         disclosure by quantifying your estimated operating expenses and/or
identifying the
         relevant factors to achieving profitability at the clinic.
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 3
Page 3
FirstName LastName
Aptorum's Lead Projects, page 2

7.       Please expand the number of columns in the development chart so that
it includes all
         phases of development that must be completed in order to market your
products (i.e.,
         Phase 2 and 3). Please make similar revisions to the chart on page 65.
8.       Please clarify the distinctions between "Target ID & Selection," "Lead
Discovery," "Lead
         Optimization" and "IND Enabling" and describe the activities conducted
at each of these
         stages.
9.       As you are in the preclinical stage of development, have not completed
your preclinical
         studies and do not intend to submit an IND application until 2020 or
2021, please revise
         your disclosure to avoid characterizing your chart as a "pipeline"
chart.
10.      We note your disclosure that "preclinical studies of ALS-1 indicate
that it inhibits the
         replication of influenza virus in vitro with a nanomolar EC50 and
protects mice challenged
         with lethal doses of avian influenza A H5N1." Please delete this
language or place this
         selected information in its full and proper context by providing the
specific details and
         parameters of the study from which the data was drawn.
11.      We note your disclosure on page 3 that "The target site on NP where
ALS-1 is acting has
         been identified and mechanism established. Animal model efficacy has
been
         demonstrated, while chemical structures are being optimized" as well
as numerous other
         statements throughout your registration statement that present your
conclusions regarding
         the safety and efficacy of your product candidates, which are
premature and inappropriate
         for you to make as these determinations are within the sole authority
of the U.S. Food and
         Drug Administration and comparable regulatory bodies. Please revise
your disclosure to
         remove these statements here and throughout your registration
statement.

         As a non-exhaustive list of examples only, we note the following
statements:
           "NLS-1 is a drug molecule derived from natural products (green tea)
which appears to
            be effective for the treatment of endometriosis..." on page 4;
           "In an animal study...oral administration of Pro-EGCG exhibits
superior efficacy over
            other conventional therapeutic agents..." on page 4;
           "Assuming our research continues to generate positive results..." on
page 63;
           "According to data in our preclinical studies...ALS-1 outperforms
oseltamivir (sold
            under the brand name Tamiflu) in cell-based assays and stops virus
replication during
            the early to late stages of viral infection..." on page 66;
           "EGCG, a naturally occurring molecule occurring extracted from green
tea, appears to
            be efficacious for the treatment of endometriosis..." on page 68;
           "The target site has been identified and animal efficacy and safety
have been
            demonstrated..." on page 72; and
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 4
Page 4
FirstName LastName
             "We intend to develop SPLS-1 as an alternative treatment for liver
cancer, which we
             believe will offer improved safety and efficacy..." on page 73.
12.      Please remove the graphics from the Summary section and discuss them
in the Business
         section where appropriate context may be provided.
Our Structure, page 5

13.      We note your disclosure that prior to the completion of the offering,
and as long as
         officers and directors own at least 50% of the voting power of the
Company's outstanding
         stock, you will qualify as a "controlled company" under Nasdaq listing
rules. Please revise
         your disclosure to clarify whether you expect to qualify as a
controlled company after the
         offering (on a minimum and maximum basis) and if so, please add a
related risk factor
         discussing the scope of the controlled company exemption from
corporate governance
         standards.
Our Securities, page 6

14.      Please expand your disclosure to discuss the concentration of voting
power due to the
         ownership of your Class B ordinary shares. Please add related risk
factor disclosure
         discussing the following risks as they relate to the concentration of
ownership of your
         Class B common shares:
           Your Class A ordinary shares may be undervalued;
           Your capital structure may have the effect of delaying or preventing
a change of
             control that shareholders may view as beneficial or result in your
Class A shares being
             undervalued; and
           Future issuances of your Class B ordinary shares may be dilutive to
holders of your
             Class A ordinary shares.
Implications of Being an Emerging Growth Company, page 7

15.      Please supplementally provide us with copies of all written
communications, as defined in
         Rule 405 under the Securities Act, that you, or anyone authorized to
do so on your behalf,
         present to potential investors in reliance on Section 5(d) of the
Securities Act, whether or
         not they retain copies of the communications.
Risk Factors
Risks related to our IP
"A significant portion of our IP portfolio currently comprises pending patent
applications and
provisional patents...", page 23

16.      We note your discussion that a significant portion of your IP
portfolio includes pending
         patent applications and provisional patents that have not yet been
issued. Please revise
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 5
Page 5
FirstName LastName
         your disclosure to identify the product candidates for which you have
obtained patents
         versus pending or provisional patents.
Use of Proceeds, page 49

17.      Please revise this section so that it provides your intended use of
proceeds of the offering
         on a minimum and maximum offering basis. Additionally, it appears from
your disclosure
         that the proceeds from the offering will not be sufficient to complete
all of your specified
         uses. Please disclose how far in the development you expect to achieve
with the proceeds
         of this offering and identify the sources of other funds needed to
complete development of
         your product and device candidates through commercialization,
development of your
         AML clinic and establishment of your self-owned laboratory. Refer to
Instruction 3 to
         Item 504 of Regulation S-K.
Capitalization, page 50

18.      You indicate that you present capitalization information on an actual,
pro forma, and pro
         forma as adjusted basis. However, your table shows columns for actual,
as adjusted
         (minimum offering amount), and as adjusted (maximum offering amount),
which do not
         match this description. Please revise, as necessary.
Dilution, page 51

19.      Please disclose the percentage of immediate dilution resulting from
the offering. Refer to
         Item 9.E of the instruction to Form 20-F.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Results of Operations (Successor Basis)
Research and Development Expenses, page 60

20.      Please disclose your research and development expense incurred by
project. If you do not
         keep track of such costs by project, disclose that fact and the costs
incurred by the types of
         costs classified as research and development.
Business
Lead Projects and Significant Projects, page 64

21.      We note your disclosure that your Project Companies have entered into
standard license
         agreements with various university and licensing entities customized
to the nature of each
         project. Given the current stage of development of your product
candidates, these
         agreements appear to be material. Please expand your disclosure to
include the material
         terms of these agreements. Additionally, please file these license
agreements as exhibits to
         the registration statement or tell us why you believe you are not
substantially dependent
         upon these agreements. Refer to Item 601(b)(10) of Regulation S-K.
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 6
Page 6
FirstName LastName
Lead Projects, page 66

22.      Please revise your disclosure of your preclinical studies for ALS-1,
ALS-4, and NLS-1 to
         remove conclusory statements regarding efficacy and to discuss the
results in terms of
         objective data points. Additionally, please tell us whether the
results shown represent
         results that were achieved consistently in the preclinical studies,
and also explain whether
         such studies were powered for statistical significance.
23.      Please ensure that the graphics presented are legible and include
legends defining
         abbreviated terms and that include relevant disclosure so that lay
readers will understand
         the graphic.
Patent License, page 66

24.      Please expand your disclosure concerning the license agreement related
to product
         candidate ALS-1 to include all material terms, including the
following:
           each parties' rights and obligations;
           financial terms, including potential milestone payments and royalty
rate or range not
             to exceed ten percent;
           duration of the agreement and royalty term; and
           termination provisions.
         Please make similar revisions to the disclosure concerning the license
agreements related
         to ALS-4 on page 68 and NLS-1 on page 71. Please also explain what you
mean by "ITF
         matching scheme" on page 71.
SLS-1: Robotic Catheter Platform..., page 73

25.      Please expand to describe the current development stage and regulatory
status of this
         device.
Intellectual Property, page 74

26.      We note your disclosure on page 68 that a U.S. provisional patent has
been filed related to
         ALS-4. We note also your disclosure on page 74 that a U.S. provisional
patent
         application was filed related to VLS-3. Please expand your disclosure
to explain what a
         provisional patent application is and whether you or another party is
actively preparing a
         patent application and, if so, when you anticipate filing this
application. Please also
         include the dates that the provisional patent applications were filed,
how the cost of a
         patent application, if any, will be funded, and the date that you will
lose the filing date
         established by the provisional patent application if a patent
application is not filed.
27.      Please expand your disclosure in the chart on page 75 to include all
patents, patent
         applications and provisional patents that are material to your
business. Refer to Item 4.B.6
         of Form 20-F.
 Ian Huen
FirstName LastNameIan Huen
Aptorum Group Ltd
Comapany NameAptorum Group Ltd
August 10, 2018
August 10, 2018 Page 7
Page 7
FirstName LastName
Important Advisors and Consultants to the Company, page 77

28.      Please expand your disclosure to identify the services provided by
each individual that are
         material to your business. To the extent these individuals do not
actively provide services
         that are material to your business, please remove these biographies or
tell us why you
         believe it is appropriate to include them.
Government Regulation, page 80

29.      We note the only disclosure regarding government regulations specific
to medical device
         testing and approval is a statement on page 81 that "devices are
subject to different forms
         of testing and approval" and must satisfy "various FDA requirements in
order to be
         brought to market." Please expand to describe the regulations specific
to the SLS-1
         robotic catheter device.
Appointment Letters, page 101

30.      Please revise to describe the material terms of each letter separately
as it appears the terms
         of the letters were not the same for each officer. For instance, we
note that Dr. Cheng
         received a stock bonus of 5% of Aptorum Medical Limited's ordinary
shares in connection
         with his appointment letter.
Transactions with Related Parties, page 101

31.      Your service agreement with Covar Pharmaceuticals Incorporated appears
to be material.
         Please file the Covar agreement as an exhibit to the registration
statement. Refer to Item
         601(b)(10) of Regulation S-K. Alternatively, please tell us why you
believe such filing is
         not required.
Description of Share Capital
Voting Rights, page 112

32.      Please revise to clarify the matters requiring a special resolution as
opposed to an ordinary
         resolution.
Anti-Takeover Provisions, page 114

33.      Please expand your disclosure to specify the limitation on the ability
of shareholders to
         convene a general meeting under your Memorandum and Articles.
Consolidated Financial Statements, page F-1

34.      Please tell us how you determined the appropriate allocation of
shareholders' equity upon
         the change in investment company status. In this regard, we note that
you allocated the
         entire net asset balance as of February 28, 2017 to ordinary shares
and APIC despite the
         fact that your net assets included undistributed ordinary income and
accumulated
 Ian Huen
Aptorum Group Ltd
August 10, 2018
Page 8
      undistributed net realized loss on investments. Explain how you
determined that no
      amounts should be allocated to accumulated deficit or accumulated other
comprehensive
      loss.
Notes to Consolidated Financial Statements (Successor Basis)
14. Summary of Significant Accounting Policies
Intangible Assets, page F-37

35.   Please provide us a detailed analysis supporting your determination that
the unpatented
      licenses have an indefinite useful life. Refer to ASC 350-30-35-4.
36.   Please confirm to us that you do not have additional obligations under
the license
      agreements. Otherwise, disclose the amount and description of the
obligations that are
      remaining, including those that are contingent. To the extent material,
such disclosure
      should also be made as contractual obligations under your MD&A liquidity
section.
Research and Development Expenses, page F-38

37.   Please tell us, if true, why you do not include amortization of the
patent license or
      depreciation of the laboratory equipment in research and development
expenses. Refer to
      ASC 730-10-25-2.
General

38.   Please provide us proofs of all graphics, visual, or photographic
information you will
      provide in the printed prospectus prior to its use, for example in a
preliminary prospectus.
      Please note that we may have comments regarding this material.
       You may contact Keira Nakada at 202-551-3659 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Christine Westbrook at 202-551-5019 or Mary Beth Breslin at
202-551-3625 with any
other questions.



                                                            Sincerely,
FirstName LastNameIan Huen
                                                            Division of
Corporation Finance
Comapany NameAptorum Group Ltd
                                                            Office of
Healthcare & Insurance
August 10, 2018 Page 8
cc:       Louis Taubman, Esq.
FirstName LastName
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
